

Continued from previous page

based demonstration projects should include—but not be limited to—implementing income-related, refundable, and affordable tax credits.

In other actions, delegates voted to:

► Seek the replacement of the Medicare payment formula's sustainable growth rate with payment updates that reflect increases in the cost of medical practice.

► Pursue caps on noneconomic damages as a top priority in medical liability reform, with a request to the board of trustees to report efforts to reform the civil justice system, as part of its coalition-building activities.

► Support federal funding of comprehensive sex education programs that stress the importance of abstinence in preventing unwanted pregnancies and sexually transmitted diseases, and that also teach about contraception and safer sex.

► Create model state legislation for physicians who testify in medical liability cases, emphasizing that they must meet statutory expert witness requirements, such as comparable education, training, and occupational experience in the same field as the defendant.

"Junk science has no place in the courtroom," said Donald Palmisano, M.D., AMA's immediate past president.

The stance on prescription drug importation and specialty hospitals provided the House of Delegates the opportunity to flex its political muscle at a time when the AMA is struggling with its identity and appeal to younger physicians.

Delegates heard the evidence for themselves in video clips of young participants in focus groups, and in new survey data, where only 11% of 800 physicians identified the AMA as a leadership body to which they could relate.

"Physicians simply aren't clear about who we are and what we do," Michael Maves, M.D., the AMA's executive vice president, said during the meeting's opening session.

In addition, "the AMA is not getting credit from physicians for the advocacy work it does," said Ajay Gupta, a principal at McKinsey & Co., a management consulting firm that conducted the survey and the focus groups.

The survey reaffirmed a longtime trend that physicians prefer their specialty or state society to a broader umbrella organization. Only 19% of the survey participants thought the AMA increased opportunities for their voices to be heard on important issues, as opposed to specialty groups (49%) and state groups (30%). In comparing current member penetration, the AMA "was fifth in the wallet behind specialty, state, and county societies," Mr. Gupta said.

Lack of confidence in the AMA has manifested in declining membership rolls. The percentage of nonrenewals in AMA membership has doubled from 10% to 20% over the last decade, with young, active physicians accounting for most of the decline. "That amounts to 430,000 physicians who are no longer members," he said.

AMA could conceivably boost its membership by focusing on medical society activists and "positive" society supporters, two groups of physicians that embrace the idea of society medicine, Mr. Gupta suggested. About 290,000 physicians represent

these "joiner" segments, though most are mature physicians, not young ones, he said.

"Joiners" have "a remarkably uniform view of what they want us to deliver: focused advocacy on priority issues, opportunities for involvement, and communications about progress and results," Dr. Maves said.


Targeting residents should be a key strategy, said Brooke Bible, the medical student representative to the AMA's political action committee. While

the AMA enjoys an excellent student constituency, "the residency period—where people get tired, jaded, or busy—is where we lose members."

The campaign begins in 2005, using surveys, town meetings, and other grassroots activities to connect with physicians, Gary Epstein, the AMA's new chief marketing officer, said in an interview. Patients in particular have always supported the AMA's charge, "and we need to leverage that" as a resource, he said. ■

## DATA WATCH

### Most Americans Do Not Trust Online Prescription Drug Market



Note: Based on a survey of 2,200 adults conducted May 14 to June 17, 2004. Sources: Pew Internet & American Life Project, Princeton Survey Research Associates

KEVIN FOLEY, RESEARCH

## For moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time

# THERE CAN BE LIFE WITH RELIEF™



- **Q12h dosing convenience**
- **Onset of analgesia within 1 hour in most patients<sup>1\*</sup>**
- **Convenient conversion and titration**
- **OxyContin® is an opioid agonist and a Schedule II controlled substance with an abuse liability similar to morphine.** Consider this when an increased risk of misuse, abuse, or diversion is a concern
- **OxyContin® Tablets are NOT intended for use as a prn analgesic**
- **OxyContin® TABLETS ARE TO BE SWALLOWED WHOLE AND ARE NOT TO BE BROKEN, CHEWED, OR CRUSHED. TAKING BROKEN, CHEWED, OR CRUSHED OxyContin® TABLETS LEADS TO RAPID RELEASE AND ABSORPTION OF A POTENTIALLY FATAL DOSE OF OXYCODONE**
- **OxyContin® 80 mg and 160 mg Tablets ARE FOR USE IN OPIOID-TOLERANT PATIENTS ONLY.** These tablets may cause fatal respiratory depression when administered to opioid-naïve patients
- The most serious risk with OxyContin® is respiratory depression, which can be fatal
- OxyContin® is not indicated for pre-emptive analgesia, pain in the immediate postoperative period (the first 12 to 24 hours following surgery) in patients not previously taking OxyContin® (because its safety in this setting has not been established), or pain that is mild or not expected to persist for an extended period of time
- As used here, "moderate" and "moderate to severe" pain do not include commonplace and ordinary aches and pains, pulled muscles, cramps, sprains, or similar discomfort

Purdue is firmly committed to maintaining the highest standards of marketing practices in the industry while continuing to advance the proper treatment of pain in America. If Purdue's marketing and sales practices fail to meet this standard, we urge you to contact us at **1-888-690-9211**.

\*From a single-dose study.

Reference: 1. Sunshine A, Olson NZ, Colon A, et al. Analgesic efficacy of controlled-release oxycodone in postoperative pain. *J Clin Pharmacol.* 1996;36:595-603.

8 AM 8 PM  
Q12h  
**OXYCONTIN® II**  
(OXYCODONE HCl CONTROLLED-RELEASE) TABLETS  
**IT WORKS**

**Please read brief summary of prescribing information, including boxed warning, on adjacent page.**

Copyright 2004, Purdue Pharma L.P., Stamford, CT 06901-3431

D7O87-F1

PUR-4001220